According to GSK plc, the FDA has given its experimental oral antibiotic, gepotidacin, Priority Review for the treatment of uncomplicated urogenital gonorrhea in individuals 12 years of age and older. With a December 2025 FDA action date, this decision expedites the review process.
The World Health Organization has designated gonorrhea as a priority pathogen, making it a serious public health problem. Injectable therapies are frequently used in the current standard of care, however not all patients may benefit from them. Gepotidacin would offer a much-needed new oral therapy option if it were approved.
Read More: U.S. FDA Approves Convenient Prefilled Syringe for GSK’s Shingles Vaccine, Shingrix
The FDA’s evaluation is based on the promising outcomes of the Phase 3 EAGLE-1 trial. Gepotidacin was shown to be equally effective as the current conventional combination therapy of oral azithromycin and intramuscular ceftriaxone, according to a study published in The Lancet. At the urogenital site, gepotidacin had a success rate of 92.6%, which was similar to the comparison regimen’s 91.2% success rate. A consistent safety and tolerability profile, free of significant drug-related side events, was also validated by the trial.
This is the second significant regulatory application for gepotidacin in the United States. The FDA authorized gepotidacin, marketed under the name Blujepa, in March 2025 for the treatment of simple UTIs in a comparable patient group. Part of the financing for the development of gepotidacin came from federal sources, such as the U.S. Department of Health and Human Services.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
